Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: An open-label phase I trial

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2175-2182

  Granel, Brigitte ^a,c   Daumas, Aurélie ^a   Jouve, Elisabeth ^a   Harlé, Jean Robert ^a   Nguyen, Pierre Sébastien ^a   Chabannon, Christian ^b   Colavolpe, Nathalie ^a   Reynier, Jean Charles ^c   Truillet, Romain ^a   Mallet, Stéphanie ^a   Baiada, Antoine ^a   Casanova, Dominique ^a   Giraudo, Laurent ^a   Arnaud, Laurent ^a   Veran, Julie ^a   Sabatier, Florence ^a   Magalon, Guy ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOLOGOUS ADIPOSE DERIVED STROMAL VASCULAR FRACTION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COCHIN HAND FUNCTION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAND DISABILITY; HAND EDEMA; HAND PAIN; HUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RATING SCALE; RAYNAUD PHENOMENON; SUBCUTANEOUS TISSUE; SYSTEMIC SCLEROSIS; AGED; AUTOTRANSPLANTATION; DISABILITY; FINGER; INJECTION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ADULT; AGED; DISABILITY EVALUATION; FEMALE; FINGERS; HUMANS; INJECTIONS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84949892793     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205681     Document Type: Article

References (39)

1. Guillevin L, Hunsche E, Denton CP, et al.; DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clin Exp Rheumatol 2013;31:71-80.
2. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-30.
3. Sandqvist G, Eklund M. Hand Mobility in Scleroderma (HAMIS) test: the reliability of a novel hand function test. Arthritis Care Res 2000;13:369-74.
4. Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006;65:1088-92.
5. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
6. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
7. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
8. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
9. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
10. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
11. Jewett LR, Hudson M, Malcarne VL, et al. Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis. PLoS One 2012;7: e33281.
12. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the Late TIME randomized trial. JAMA 2011;306:2110-19.
13. Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008;156:1010-18.
14. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012;308:2369-79.
15. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011;92:26-36.
16. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-95.
17. Kapur SK, Katz AJ. Review of the adipose derived stem cell secretome. Biochimie. 2013;95:2222-8.
18. Leto Barone AA, Khalifian S, Lee WP, et al. Immunomodulatory effects of adipose-derived stem cells: fact or fiction?. Biomed Res Int 2013;2013:383685.
19. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014;16:245-57.
20. Scuderi N, Ceccarelli S, Onesti MG, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant 2013;22:779-95.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
22. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
23. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
24. Rannou F, Poiraudeau S, Berezné A, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
25. Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013;15:641-8.
26. Kapandji A. Clinical test of apposition and counter-apposition of the thumb Cotation clinique de l'opposition et de la contre-opposition du pouce. Ann Chir Main 1986;5:67-73.
27. Mathiowetz V, Kashman N, Volland G, et al. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 1985;66:69-74.
28. Lee P, Leung FY, Alderdice C, et al. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol 1983;10:930-8.
29. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
30. Georges C, Chassany O, Mouthon L, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
31. Katz AJ, Tholpady A, Tholpady SS, et al. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 2005;23:412-23.
32. Lee SH, Lee EJ, Lee SY, et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res 2014;40:117-25.
33. Ikegame Y, Yamashita K, Hayashi S, et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011;13:675-85.
34. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292-8.
35. Nakagami H, Maeda K, Morishita R, et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005;25:2542-7.
36. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
37. Lin K, Matsubara Y, Masuda Y, et al. Characterization of adipose tissue-derived cells isolated with the Celution system. Cytotherapy 2008;10:417-26.
38. Larghero J, Farge D, Braccini A, et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008;67:443-9.
39. Cipriani P, Di Benedetto P, Liakouli V, et al. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol 2013;173:195-206.